Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2010

Novartis Plans Filing for Myelofibrosis Candidate in Light of Positive Phase III Data

  • Novartis says it plans to file for approval of its myelofibrosis (MF) therapy candidate INC424 worldwide during 2011 on the back of positive data from a Phase III trial. The firm is developing the drug for non-U.S. markets under license from Incyte.

    The pivotal Comfort-1 study showed treatment with INC424 led to significant reductions in spleen size in patients with primary MF, post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). The secondary endpoint of symptomatic improvements measured by the modified Myelofibrosis Symptom Assessment Form Diary, was also met.

    INC242 has been granted orphan drug status for MF by both FDA and the European Medicines Agency.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »